NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) : FUND RAISING MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR THE "COMPANY") PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN MGRC, REPRESENTING NOT MORE THAN 20% OF THE ENLARGED NUMBER OF ISSUED SHARES IN MGRC (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PROPOSED PRIVATE PLACEMENT")
@saferisk fund managers have their policy. Cannot post on i3 except foreign hedge funds. Either you’re fake or you’re spewing BS. So you’re behind MGRC la I write down first
franky speaking, no fundamental support for this stock. the only story is the CAR-T cancer product that can making some story. Company wise not a very good and poor management. Obviously is manipulate by some fund before to push and dump all the share to retailers who chasing high.
What do you mean by poor management? This is not a mature company so definitely expect some inexperienced executive level employees. Also, genomics technology is in the infancy stage in Malaysia. Yes, this company has bad financials but once this sector gains traction and popularity, good luck buying genomic-related companies at this price.
Same with any blue chip companies, they start out small and with almost no asset. They grow slowly and with experience. Investors must endure the pain and effort of the management if they want to reap the maximum profit. Takes time though.
I am not going to buy more shares of this company and will only hold as my cost is rather low. Not going to sell. Took small profits at 1.2
Eostre 7M to boost company’s financial health. Company won’t go into PN17 anymore. This is a once in a lifetime turnaround investment opportunities. Monday buy another 1M shares let’s go
I am no contra or day trader. I've been quietly buying. Hope the management provide us with update on the Eostre right of use deal and address any regularisation plans to boost investor confidence. Bullish in the medium term
It is now evident that CAR-T therapy has revolutionized cancer research and treatment. Within a few years, substantial progress has been made, particularly for patients with certain hematological malignancies who had progressed after several lines of therapies and had almost exhausted all potential treatments. Furthermore, there are new indications for continued success of CAR-T therapies. For example, beyond just the expected efficacy of CAR-Ts, the finding that CAR-Ts can be in circulation in the central nervous system provides a hope that the therapy can (a) be effective in suppressing possible central nervous system relapses and (b) potentially be tested against primary central nervous system cancers, as well as central nervous system lymphomas. Furthermore, even though the current approved CAR-T therapies target CD19, there are data to suggest that CAR-T therapy might still be a great therapy for patients who have progressed on other CD19-targeting therapies. Thus, the patients who have progressed on other CD19-targeting therapies still have hope. Among the main challenges associated with CAR-T therapy that still need to be addressed are the several toxicities. These toxicities have led to evaluation of the quality of life in treated patients Source: CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas, International Journal of Molecular Science
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
New IPO: Building management systems (BMS), solar thermal systems and energy-saving services provider, Solar District Cooling Bhd aims to list on the Ace Market!
MQ Trader 282 views | 1 d ago
0:17
New IPO: The onshore and offshore support services provider for the O&G industry, Steel Hawk Bhd aims to list on the Ace Market!
MQ Trader 11448 views | 10 d ago
0:17
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
investopology
1,978 posts
Posted by investopology > 2021-03-16 09:53 | Report Abuse
https://www.bfm.my/podcast/morning-run/the-breakfast-grille/can-mgrc-personalize-medicine
Boss very hardworking, but share price drop like shit